The Endocannabinoid System Exerts Anti-Inflammatory and Pro-Apoptotic Effects on Synovial Fibroblasts in Rheumatoid Arthritis by Apitz, Martin

Aus dem Lehrstuhl für Innere Medizin I
Prof. Dr. Martina Müller-Schilling
der Fakultät für Medizin
der Universität Regensburg
The Endocannabinoid System
Exerts Anti-Inflammatory and Pro-Apoptotic
Effects on Synovial Fibroblasts in Rheumatoid
Arthritis
Inaugural-Dissertation
zur Erlangung des Doktorgrades
der Medizin
der
Fakultät für Medizin
der Universität Regensburg
vorgelegt von
Martin Apitz
2015

Aus dem Lehrstuhl für Innere Medizin I
Prof. Dr. Martina Müller-Schilling
der Fakultät für Medizin
der Universität Regensburg
The Endocannabinoid System
Exerts Anti-Inflammatory and Pro-Apoptotic
Effects on Synovial Fibroblasts in Rheumatoid
Arthritis
Inaugural-Dissertation
zur Erlangung des Doktorgrades
der Medizin
der
Fakultät für Medizin
der Universität Regensburg
vorgelegt von
Martin Apitz
2015
Dekan: Prof. Dr. Dr. Torsten E. Reichert
1. Berichterstatter: Prof. Dr. Rainer H. Straub
2. Berichterstatter: Prof. Dr. Dr. h.c. Joachim Grifka
Tag der mündlichen Prüfung: 10.11.2015



Contents
1 Deutsche Zusammenfassung 1
2 Introduction 5
2.1 Rheumatoid Arthritis: Think Global, Act Local . . . . . 5
2.1.1 General Definition . . . . . . . . . . . . . . . . . . 5
2.1.2 Epidemiological and Economic Relevance . . . . . . 5
2.2 Pathogenesis of Rheumatoid Arthritis . . . . . . . . . . . 8
2.2.1 Prearthritic Phase . . . . . . . . . . . . . . . . . . 8
2.2.2 Loss of Tolerance Phase . . . . . . . . . . . . . . . 10
2.2.3 Arthritic Phase . . . . . . . . . . . . . . . . . . . . 12
2.2.4 Conclusion: Importance of Fibroblasts . . . . . . . 15
2.3 The Role of Synoviocytes in Rheumatoid Arthritis . . . . 16
2.3.1 Training the Bad Boy: Proliferation, Cell Death and
Destruction . . . . . . . . . . . . . . . . . . . . . . 16
2.3.2 The Inner Ambition: MAPK, CREB and Their Role
in Survival, Invasion and Destruction . . . . . . . . 20
2.3.3 Conclusion: Synoviocytes as a Therapeutic Target . 23
2.4 The Endocannabinoid System . . . . . . . . . . . . . . . 24
2.4.1 The Cannabinoid Receptors . . . . . . . . . . . . . 24
2.4.2 The Endogenous Ligands . . . . . . . . . . . . . . . 25
2.4.3 General Effects . . . . . . . . . . . . . . . . . . . . 26
2.4.4 Conclusion: Using Complexity . . . . . . . . . . . . 27
2.5 Conclusion: Synergy is Energy . . . . . . . . . . . . . . . 28
2.6 Purpose and Goal: From Pathogenesis to Treatment . . . 28
i
ii Contents
3 Materials and Methods 29
3.1 Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2 Cell Culture . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2.1 Tissue Preparation . . . . . . . . . . . . . . . . . . 33
3.2.2 Cryopreservation and Thawing . . . . . . . . . . . 33
3.2.3 Cell Culturing . . . . . . . . . . . . . . . . . . . . . 34
3.3 Detection of Intracelluar Activation of ERK, p38, c-JUN
and CREB . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.4 LDH Cytoxicity Detection . . . . . . . . . . . . . . . . . 35
3.5 Flow Cytometry with Annexin V and Propidium Iodide . 35
3.6 Proteome Profiler: Human Phosphokinase, Apoptosis and
Human Cytokine Kit . . . . . . . . . . . . . . . . . . . . 35
3.7 Statistical Analysis . . . . . . . . . . . . . . . . . . . . . 36
4 Results and Discussion 37
4.1 The Predominance of ERK . . . . . . . . . . . . . . . . . 37
4.2 The Antagonistic Effects of CB1 and CB2 on p38 . . . . . 38
4.3 The Antagonistic Effects of Anandamide . . . . . . . . . 42
4.3.1 Blocking the Recycling of AEA with JNJ Decreased
MAPK Phosphorylation . . . . . . . . . . . . . . . 42
4.3.2 Repression of Downstream Proteins . . . . . . . . . 43
4.4 Conclusion: The Activation Pattern of AEA Resembled
CB1 and CB2 . . . . . . . . . . . . . . . . . . . . . . . . 45
4.5 Activation of MAPKMainly by CB1 in Rheumatoid Arthri-
tis Synovial Fibroblasts . . . . . . . . . . . . . . . . . . . 46
4.5.1 Rheumatoid Arthritis Synovial Fibroblasts Are More
Prone to Stimulation . . . . . . . . . . . . . . . . . 46
4.5.2 The CB2 Agonist Activated ERK and CREB only
in Rheumatoid Arthritis Synovial Fibroblasts . . . 46
4.5.3 The CB2 Agonist and the FAAH Inhibitor JNJ Ac-
tivated ERK but Suppressed p38 . . . . . . . . . . 46
4.5.4 AEA and the CB1 Agonist Showed Broadest Acti-
vation of MAPK . . . . . . . . . . . . . . . . . . . 48
Contents iii
4.6 Conclusion: CB1 Agonism is Mainly Responsible for Ac-
tivation of MAPK and CREB in Synovial Fibroblasts . . 50
4.7 Consequences on Apoptosis and Cytokine Secretion . . . 50
4.7.1 CB1 Agonism Induced Apoptosis and Necrosis . . . 50
4.7.2 AEA-Attenuated Expression of Key Cytokines Af-
ter Stimulation by TNF𝛼 . . . . . . . . . . . . . . 51
4.8 Pathogenesis: The ECS and Immune System . . . . . . . 55
4.9 Therapy: CB2 Agonism and the Anti-Inflammatory Treat-
ment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5 Summary and Outlook 57
Abbreviations 59
List of Figures 61
List of Tables 63
Bibliography 65

Deutsche Zusammenfassung
Die Rheumatoide Arthritis ist eine häufige Autoimmunerkrankung,
die 0,5-1 % der erwachsenen Bevölkerung betrifft und als chronische
Gelenkentzündung zu fortschreitender Gelenkzerstörung und systemi-
schen Symptomen wie z.B. das metabolisches Syndrom und Athero-
sklerose führt. In den letzten Jahrzehnten wurde das pathogenetische
Verständnis der Rheumatoiden Arthritis auf Nicht-Immunzellen erwei-
tert. So besetzen Fibroblasten der artikulären Synovia eine heraus-
ragende Stellung in der Entwicklung der Gelenkentzündung. Im Zu-
sammenspiel mit Immunzellen und Osteoklasten entwickelt sich im
chronisch entzündeten Gelenk ein Gewebetumor aus tumorös verän-
derten Fibroblasten, der Pannus. Diese veränderten Fibroblasten sind
verantwortlich für die Synthese von Matrix-Metalloproteasen MMP,
die Kapsel- und Knorpelmatrix degradieren. Die Fibroblasten hal-
ten die lokale Arthritis aufrecht und koordinieren die Zerstörung an-
grenzenden Knochens durch die Osteoklasten. Die Unterbindung im-
munologischer Kommunikation durch sogenannte Biologika wie z.B.
TNF𝛼-Hemmer, hat das therapeutische Ergebnis deutlich verbessert,
die therapeutischen Kosten jedoch auch deutlich erhöht und schwer-
wiegende Nebenwirkungen der Immunsuppression eingeführt. Deshalb
besteht weiterhin die Notwendigkeit, alternative und adjuvante Thera-
pien zu entwickeln, die nicht nur auf das Immunsystem sondern auch
auf nicht-immunologische Zellen wie die Fibroblasten abzielen. Einer
der wichtigsten therapeutischen Ergebnisse muss es sein, dass diese Fi-
broblasten weniger aggressiv wachsen und weniger gewebezerstörende
MMP bilden. Intrazellulär wird die Synthese von MMP hauptsäch-
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lich durch mitogen-aktivierte Proteinkinasen MAPK gesteuert. Dieses
System besteht aus Proteinkinasen, die sich nach extra- oder intrazel-
lulärem Signal konsekutiv und exponentiell aktivieren. Grundsätzlich
lassen sich hierbei drei Kinase-Achsen unterscheiden: die Extracellular-
Signal Regulated Kinase ERK, die hauptsächliche für Zellwachstum
und Zelldifferenzierung verantwortlich ist, sowie die p38 MAPK und
c-Jun N-Terminal Kinase JNK, die die zelluläre Antwort auf Stress ko-
ordinieren. Assoziiert ist das cAMP-responsive Binding Protein CREB,
das ebenso durch zellulären Stress aktiviert wird.
Somit kann ein therapeutischer Ansatz die Reduktion der Aktivität
des MAPK-System in den synovialen Fibroblasten sein, um damit die
Produktion von MMP zu reduzieren und die Gelenkszerstörung zu ver-
langsamen.
Das endogene Cannabinoidsystem ECS wurde im Zuge der Cannabis-
Forschung entdeckt und stellt ein komplexes Signalsystem aus Lipiden
dar. Es besteht neben den Cannabinoid-Rezeptoren CB1 und CB2 aus
den endogen produzierten Liganden Anandamid und 2-Arachidonylgly-
cerol. Dieses System moduliert sowohl zentralnervös die Nahrungsauf-
nahme als auch peripher das Immunsystem. Es konnte gezeigt werden,
dass synthetisch hergestellte Cannabinoide in Immunzellen und Nicht-
Immunzellen einiger chronischen Entzündungen, wie der Rheumatoi-
de Arthritis, suppressiv auf die Aktivität der MAPK und Produktion
von MMP wirken. Hingegen wurde die Rolle der endogen produzier-
ten Liganden in der Rheumatoiden Arthritis bislang nur unzureichend
erforscht.
Diese Arbeit verwendete humane Fibroblasten aus Patienten mit Rheu-
matoider Arthritis oder degenerativer Arthrose. Im normoxischen und
hypoxischen Umfeld wurden diese Zellen mit selektiven CB1- und CB2-
Agonisten sowie dem endogen produzierten Anandamid vorbehandelt
und zuletzt mit den pro-inflammatorischen Zytokinen TNF𝛼, Inter-
leukin-1𝛽 oder dem Endotoxin Lipopolysaccharid stimuliert. Die Ak-
tivität der intrazellulären MAPK ERK, p38, c-Jun und der cAMP-
responsive Binding Protein CREB wurde mittels Enzyme-linked Im-
3munosorbent Assay ELISA und Proteome Profiler™ gemessen. Des
weiteren wurde der Anteil apoptotischer und nekrotischer Zellen mit-
tels Durchflusszytometrie und Messung der Laktatdehydrogenase so-
wie die Synthese einiger immunmodulatorischer Zytokine mit dem Pro-
teome Profiler™ bestimmt.
Diese Arbeit zeigte, dass der CB1-Agonist die Aktivität der MAPK
nach Zytokin-Stimulation signifikant erhöhte, der CB2-Agonist jedoch
die Aktivität von MAPK und CREB signifikant erniedrigte. Das en-
dogen produzierte Anandamid wirkte in hohen Konzentration (1 µm)
wie der CB1-Agonist pro-inflammatorisch, in niedrigen Konzentration
(0.1 nm) jedoch wie der CB2-Agonist anti-inflammatorisch. Ananda-
mid konnte ebenso die Produktion von pro-inflammatorischen Zytoki-
nen nach Stimulation mit TNF𝛼 reduzieren. Des weiteren induzierten
sowohl der CB1-Agonist als auch Anandamid Apoptose und Nekrose
in den Fibroblasten.
Erstmals konnte in dieser Arbeit gezeigt werden, dass das endogen
produzierte Cannabinoid Anandamid konzentrationsabhängig entwe-
der pro- oder anti-inflammatorisch auf synoviale Fibroblasten wirkt.
Mögliche adjuvante Therapien mit Cannabinoiden gegen die Rheuma-
toide Arthritis müssen somit die lokale Konzentration von endogenen
Cannabinoiden und daher die Aktivität des ECS in der Arthritis be-
rücksichtigen. Eine klare Aussage ist in Anbetracht der Komplexität
des ECS sowie fehlender in-vivo-Experimente noch nicht möglich. Je-
doch stellt die Modulation des ECS mit seinen vielfältigen Wirkun-
gen nicht nur auf Immunzellen, sondern auch auf Nicht-Immunzellen,
wie die Fibroblasten, ein mögliches zukünftiges Therapieziel gegen die
Rheumatoide Arthritis dar.

Introduction
2.1 Rheumatoid Arthritis: Think Global, Act Local
2.1.1 General Definition
Rheumatoid arthritis is a chronic, autoimmune-induced subset of
diseases of yet-unknown origin, which is characterised by
a systemic inflammation, with antibody production as well as pul-
monary or cardiovascular complications and
a local inflammation, in the joint with cartilage and bone destruction
of small joints of hand and feet,
(McInnes et al., 2011) which altogether leads foremost to debilitating
deformities of hands and feet, alongside a 3.17-fold risk of myocardial
infarction (Maradit-Kremers et al., 2005) and stroke events, both
with more lethal outcome (Davis et al., 2008). These extra-articular
complications are largly responsible for higher mortality ratios ranging
from 1.28 to 2.98, compared with the normal population (Gabriel
et al., 2009).
2.1.2 Epidemiological and Economic Relevance
Rheumatoid arthritis affects around 0.5-1 % of the adult population
in developed countries (Gabriel et al., 2009). Due to the long-term
therapy required, the debilitating course of the disease and the high co-
morbidity, mean healthcare expenditures per patient with RA per year
in Europe and Northern America are estimated to be AC 4000-6000. In
Germany, expenditures for patients with RA range from AC 2437–2981
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annually per patient of working age, to an estimated AC 2121 per year
for patients in retirement, as of 2002 (Furneri et al., 2012; Huscher
et al., 2014).
Although the new biological therapeutics have overall reduced disease
activity and, concomitantly, hospitalisation and work absence, the eco-
nomic benefit was counterbalanced by 3- to 6-fold increases in treat-
ment cost (Ziegler et al., 2010; ter Wee et al., 2012; Hagel et al.,
2013).
Despite these positive trends in the therapeutic outcome, functional
debilitation and thus work absence are still severe in rheumatoid arthri-
tis, so that these patients still rank among patients with chronic is-
chaemic heart disease and multiple sclerosis, with respect to reduction
of health utility in quality of life (Huscher et al., 2006; Furneri et
al., 2012).
These stastistics demonstrate an ongoing need for new, less expensive
combinations of treatments to reduce climbing expenditures and eco-
nomic burden, to help decreasing disease activity, and to foster quality
of life and long-term survival for patients with rheumatoid arthritis.
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Figure 2.1: The Multistep Pathogenesis of Rheumatoid Arthritis (McInnes et al., 2011). ACPA
denotes anti-citrullinated peptide antibodies and RF rheumatoid factor. Silica Dust was added to the
original picture.
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2.2 Pathogenesis of Rheumatoid Arthritis
In recent years, our insight into the pathogenesis and etiology of RA
has increased tremendously. With different clinical presentations and
distinct genetic and environmental risk factors, RA can now be seen
as a group of different diseases that share a common final pathway
of inflammation and joint destruction (Scott et al., 2010; van der
Helm-van Mil et al., 2008).
Although a comprehensive pathogenetic model has not yet been de-
veloped, evidence is now enlarging the picture and including mes-
enchymal cells like fibroblasts and osteoclasts in the inflammatory
process. McInnes and Schett (McInnes et al., 2011) present three
crucial phases in the development of RA (Figure 2.1).
Prearthritic Phase: Genetic predisposition, environmental exposure and
combined epigenetic alteration lead to autonomous protein citrul-
lination.
Loss of Tolerance Phase: Auto-antibodies are processed and secreted,
especially ACPA against citrullinated proteins.
Arthritic Phase: Further biomechanical, microvascular, infectious or
neuroendocrinological factors result in the clinical presentation of
local and systemic inflammation.
2.2.1 Prearthritic Phase
Genetic Predisposition Twin studies revealed concordance rates of 15-
30 % in monozygotic twins against 5 % in dizygotic twins (MacGre-
gor et al., 2000). Currently, the most important filial risk factor
are HLA-DR𝛽 chain alleles that have the common protein sequence
QKRAA, which is called the shared epitope (Gregersen et al., 1987).
The biological link to an increased susceptibility is still unknown. How-
ever, the shared epitope works as a signal-transducing ligand for cal-
reticulin in leukocytes, which plays a vital role in the elimination of
apoptotic cells and can therefore be regarded as crucial for the devel-
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Figure 2.2: The Mechanism of Epigenetics in Rheumatoid Arthritis (Grabiec et al., 2013)
opment of peripheral autoimmunity (Almeida et al., 2010). Further
risk factors for rheumatoid arthritis include genetic modifications in
the STAT4 signaling pathway (Remmers et al., 2007) and in T-cell
activation, e.g. via PTPN22 (Begovich et al., 2004). As the low
concordance rates for mono- and dizygotic twins above suggest, the
exposure to diverse environmental factors mainly influence the patho-
genesis and onset of RA.
Environmental Influence In addition, a host of infectious and non-
infectious causes have been marked as risk factors for developing rheuma-
toid arthritis (see Table 2.1). Particularly, environmental exposure to
bronchial stress such as smoking or silica dust increases the risk of
developing RA in patients with susceptibility HLA alleles, such as
HLA-DR1 and the shared epitope sequence or other HLA-DR4 alleles
(Klareskog et al., 2006; Källberg et al., 2011). The bronchial
stressors might induce citrullination of mucosal proteins through post-
translational processing and modification of e.g. the peptidyl argi-
nine deiminase type IV PADI4, which is required for ACPA develop-
ment, the most specific auto-antibody involved in RA (McInnes et
al., 2011). Also, the new field of epigenetics might provide insight into
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this field of gen-environment interactions in the future.
Linking together: Epigenetics The transcription is regulated mainly
by the three mechanisms: DNA methylation, histone acetylation and
miRNA expression. These so-called epigenetic changes are responsible
for the access and binding of transcription factors and therefore create
a phenotype without altering the DNA code (Grabiec et al., 2013).
They are considered crucial in two ways (Bottini et al., 2013):
Etiologically, they provide a linkage mechanism: they explain how en-
vironmental exposure over time and family genetic predispositions
create an individual risk for rheumatoid arthritis. The epigenetic
machinery functions as a filter, which selects gene expression and
therefore the cell phenotype, depending on the environmental cir-
cumstances (Figure 2.2).
Pathogenically, they are involved in the transformation of leukocytes
and especially synovial fibroblasts into aggressive behaviour, which
is described in detail in Section 2.3.
As a consequence, external influences and internal genetic predisposi-
tions in the development of RA cannot be clearly differentiated. The
personal and local environment can have a long-term impact on the in-
ternal genetic susceptibility to RA, therefore modulating its individual
risk and variability.
2.2.2 Loss of Tolerance Phase
Citrullination 𝛼-Enolase, keratin, fibrinogen, fibronectin, collagen, and
vimentin are prone to self-citrullination, against which ACPA anti-
bodies are secreted. Citrullinated 𝛼-enolase is highly associated with
ACPA-positive RA as well as the risk factors described in Section 2.2.1
(Mahdi et al., 2009). ACPA itself has been shown to be one of the
highest predictors of early-onset RA (van der Linden et al., 2009).
Transition to Arthritic Phase It remains unclear why the systemic
loss of tolerance, alongside with the prodution of auto-antibodies such
2.2 Pathogenesis of Rheumatoid Arthritis 11
Table 2.1: Environmental Risk Factors for Rheumatoid Arthritis
Associated Factor Mechanistic Link References
Infectious Causes
Various Bacterial and Virus Infection Molecular Mimikry, such as microbial
HSP60 as an epitope to HLA-DR4
(Kamphuis et al.,
2005)
Periodontal Infection with Porphy-
romonas gingivali
Porphyromonas gingivali produces
PADI4, therefore promoting citrulli-
nation of 𝛼-enolase and fibrinogen
(Wegner et al.,
2010)
Altered Gastrointestinal Microbiota Gastrointestinal bacteria might influ-
ence the epithelial and mucosal perme-
ability and the local immune cells
(Yeoh et al.,
2013)
Non-infectious Causes
Bronchial stress such as smoking or silica
dust
Bronchial stressors such as smoking
(21-fold risk for RA) or silica dust (1.5-
to 2.5-fold risk alone, 7-fold risk to-
gether with smoking) lead to citrul-
lination of mucosal proteins through
post-translational processing and modifi-
cation of e.g. PADI4, which induces the
development of ACPA
(Klareskog et
al., 2006; Stolt
et al., 2010)
Adverse life events and chronic inflamma-
tion
Neuroimmunological involvement along
the hypothalamic-pituitary-adrenal
stress system and sympathetic nerve
system, leading to a dysbalance and
increase of energy allocation to the
immune system
(Capellino
et al., 2010;
Straub et al.,
2010; Stefanski
et al., 2013;
Straub, 2014)
as ACPA and RF, particularly affects small joints of metacarpalia
and metatarsalia. Biomechanical characteristics of these joints can
have an influence on the local microcirculation and protein metabolism
(McInnes et al., 2011). Straub et al. (Straub, 2007, 2014) proprose
a close connection between the onset and course of inflammation as
well as the energy allocation. In short-term inflammatory conditions
the systemic energy allocation shifts to the immune system. In chronic
inflammatory conditions, the energy regulation becomes impaired by
means of permanent high levels of pro-inflammatory cytokines and
high activity of the sympathetic nerve system and hypothalamic-pitui-
tary-adrenal axis with high cortisol level (Straub et al., 2010). The
imbalance of the energy expenditure pathways contributes to common
systemic features of RA such as diabetes mellitus and insulin resistance
or the development of obesity and muscle wasting, since these neuro-
humoral pathways meet the increased glucose demand for the immune
system (Straub et al., 2010). Also, the sympathetic nerve system
contributes to the local arthritic activity time-dependently and there-
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fore establishes a connection between the central nervous system and
the local immune system, in the joint as well as in secondary lymphatic
organs (Schaible et al., 2014). It directly exerts a pro-inflammatory
effect in early arthritis, but exerts an anti-inflammatory effect in later
arthritic stages (Härle et al., 2005). Since sympathetic nerve density
in the joint and the lymphoid organs is reduced in late arthritis, the
influence of the central nervous system together with its control of
energy allocation might become lost in later arthritis and replaced by
alternative regulatory mechanisms such as tyrosine-hydroxylase posi-
tive cells (Schaible et al., 2014; Pongratz et al., 2013).
2.2.3 Arthritic Phase
The main characteristic of RA is the highly inflamed joint containing
high amounts of pro-inflammatory cytokines and tissue-degrading en-
zymes (Scott et al., 2010). Three parties can be identified as main
factors in the development of arthritis: leukocytes, fibroblasts and
osteoclasts (Figure 2.3).
The Instigators: Leukocytes Regarding the adaptive immune system,
expanding synovial myeloid and dendritic cells create a T-cell promot-
ing environment and dominance of TH-17 cells, whose secreted IL-17
- together with TNF𝛼 - activates fibroblasts, chondrocytes and osteo-
clasts to produce tissue-degrading enzymes, cytokines such as IL-6,
chemokines and growth factors (Miossec et al., 2009; Hot et al.,
2011).
Furthermore, autoreactive T-cells against citrullinated protein have
been found, suggesting that the cellular immune system is directly in-
volved (Cantaert et al., 2009).
B-cells are not only responsible for the production of auto-antibodies,
but also for the presentation of the auto-antigen and for cytokine pro-
duction itself (McInnes et al., 2011).
Macrophages help to sustain inflammation by cytokine expression and
antigen presentation. They directly destroy tissue by producing reac-
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Figure 2.3: Three vital players in Rheumatoid Arthritis. ADAMTS denotes a disintegrin and
metalloprotease with thrombospondin-1–like domains, DAMP damage-associated molecular pattern,
Dkk-1 dickkopf-1, FcR Fc receptor, Fc𝜀RI high-affinity IgE receptor, FGF fibroblast growth factor,
GM-CSF granulocyte–macrophage colony-stimulating factor, HA hyaluronan, HSP heat-shock protein,
IFN-𝛼/𝛽 interferon-𝛼/𝛽, MMP matrix metalloproteinase, NLR nucleotide-binding oligomerization
domain–like receptor, PAMP pathogen-associated molecular pattern, PAR2 protease-activated receptor
2, PDGF platelet-derived growth factor, RANKL receptor activator of nuclear factor 𝜅B ligand, TGF-𝛽
transforming growth factor 𝛽, Th0 type 0 helper T cell, Th1 type 1 helper T cell, Th17 type 17 helper
T cell, TLR toll-like receptor, TNF-𝛼 tumor necrosis factor 𝛼, and VEGF vascular endothelial growth
factor (McInnes et al., 2011).
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tive oxygen intermediates and degrading enzymes (Haringman et al.,
2005; McInnes et al., 2011).
Neutrophil Granulocytes are predominant in the synovial fluid, where
they support inflammation and sustain cartilage destruction with a
host of cytokines, reactive oxygen species and proteases (Eyles et al.,
2006; Cornish et al., 2009).
In conclusion, leukocytes generate the highly inflammatory and hy-
poxic environment that is regarded as the foundation for the develop-
ment of aggressive fibroblasts.
The Culprits: Fibroblasts The joint capsule and the bone are attached
to each other by the synovium, which is organised into a dense lining
layer and a loose sublining stroma. Fibroblasts are of mesenchymal ori-
gin and tasked with producing and modelling the extracellular matrix
of the organic stroma. Thereby, they provide a scaffold for the spe-
cialised cells in almost every organ, maintain extracellular homeostasis
and integrate stimuli on the microenvironment such as pH reduction
or oxygenic stress due to inflammation (Firestein et al., 2012).
The fibroblasts compose the synovial lining without a basement mem-
brane, tight junctions or desmosomes, yet they are riveted together by
cadherins such as cadherin-11, and various integrins and receptors of
the Ig superfamily, e.g. ICAM and VCAM. These cellular structures
play a key role not only in the attachment of the synovial lining, but
also in the intracellular signaling and in the regulation of inflamma-
tion (Lee et al., 2007; Chang et al., 2011).
In later arthritic stages, the synovial lining undergoes a dramatic inva-
sion of T cells, dendritic cells and B-cells forming germinal centers, and
particularly macrophage-like and fibroblast-like synoviocytes (Take-
mura et al., 2001). All of them migrate, proliferate and increase
local joint cellularity by a ten-fold (Firestein et al., 2012). Thereby,
the arthritic environment is marked by pro-angiogenic factors and is
extensively vascularised. But it remains hypoxic, produces reactive
oxygen species and creates chronic oxidative stress on resident fibrob-
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lasts (Taylor et al., 2005).
While the synovitis unfolds, Firestein (Firestein, 2003) suggest a
direct interaction of macrophage-like synoviocytes and fibroblast-like
synoviocytes under the regulation of primarily T-cells. This interac-
tion has turned out to be more complex, since the innate immune
system and adjacent bone and cartilage cells are involved as well. The
initial site and onset mode of joint arthritis are still unknown.
The persistently inflamed and hypoxic environment changes the syn-
oviocytes, which in turn proliferate and amass a structure called pan-
nus, at which cartilage, ligaments and bone masses are progressively
damaged.
The Masons: Osteoclasts Two theories were prompted by Schett and
Firestein on the topic of fibroblast-osteoclast relationships (Schett
et al., 2010). Depending on the first affected site, synovial inflamma-
tion can spread to the bone marrow and induce osteitis. Otherwise,
primary osteitis can expand to the joint space and induce synovitis.
Kleyer et al. (Kleyer et al., 2014) have coined these differing con-
cepts as the hen-egg dilemma. Accordingly, further research is required
to discern the prearthritic phase as local or systemic.
2.2.4 Conclusion: Importance of Fibroblasts
In conclusion, fibroblast-like synoviocytes play a vital role in the
development and progression of rheumatoid arthritis and are the key
players in local joint and bone destruction, alongside the immune sys-
tem. Although RA is an autoimmune disease, not only should the
modulation and suppression of leukocytic activity be considered for
therapeutic intervention, but, eventually, decreasing the activity of fi-
broblasts and osteoclasts may be key to an effective therapeutic strat-
egy.
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2.3 The Role of Synoviocytes in Rheumatoid Arthritis
2.3.1 Training the Bad Boy: Proliferation, Cell Death and
Destruction
Fibroblast-like synoviocytes are also called synovial fibroblasts (SF)
and are key factors in the maintenance of local inflammation as well
as in the destruction of adjacent bone and cartilage structures.
Whereas macrophage-like synoviocytes produce a range of pro-inflam-
matory cytokines, chemokines and growth factors, fibroblast-like syn-
oviocytes respond with the secretion of their own host of cytokines,
such as IL-6, and matrix degrading enzymes. The autocrine and
paracrine circle sustains inflammation and fosters proliferation of syn-
ovial tissue to a pannus at the cartilage-bone borders (Figure 2.3 and
2.4).
In the course of arthritis, fibroblast-like synoviocytes respond to the
highly inflammatory environment by a changed behaviour in gene ex-
pression and cell characteristics. Effectively, they are trained to be
imprinted aggressors (Bottini et al., 2013).
The pannus is composed of macrophages, osteoclasts and fibroblast-
like synoviocytes and shows characteristics of a local invasive tumour
with ongoing destruction of cartilage surface by fibroblast-like synovio-
cytes and bone surface by osteoclasts (Figure 2.3).
The Boot Camp: Inflammatory Synovia Fibroblast-like synoviocytes
play the central role in sustenance of inflammation and in bone and
cartilage destruction (Lee et al., 2007). They are part of the cytokine
cycle and are one of the essential sources of IL-6 in arthritis (Nishi-
moto et al., 2004).
IL-6 and TNF𝛼, as well, are pleiotropic cytokines that moderate the
immunological response in inflammation, haematopoesis and oncolog-
ical diseases (Kishimoto, 1989; Nishimoto et al., 2000). IL-6 medi-
ates between endothelial cells and SF, which, in turn, induce greater
neutrophil recruitment in the synovia (Lally et al., 2005). SF are
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Figure 2.4: Autocrine and Paracrine Cytokine Network in the Synovial Layer. FGF denotes fibroblast
growth factor, GM-CSF granulocyte macrophage colony-stimulating factor, IFN-𝛾 interferon 𝛾, IL
interleukin, IL-1Ra interleukin 1 receptor antagonist, M-CSF macrophage colony-stimulating factor,
sTNF-R soluble tumor necrosis factor receptor, TGF-𝛽 transforming growth factor 𝛽 and TNF-𝛼
tumor necrosis factor 𝛼 (Firestein, 2003).
responsible for the chemoattraction of monocytes by means of CCL2
(MCP-1) secretion (Villiger et al., 1992) and for T-cell recruitment
by means of CCL5 secretion (Patel et al., 2001).
These properties reflect their physiological role in the selection and
recruitment of leukocytes and in the survival and differentiation of,
for example, B cells, which are dependent on IL-6 stimulation by fi-
broblasts in their immature stage (Firestein et al., 2012).
Fibroblasts are paramount in the prolonged survival and retention of
leukocytes, as they produce Interferon-𝛼 and Interferon-𝛽 (Buckley
et al., 2001), CXCL12 and its receptor CXCR4 (Burger et al., 2001;
Ohata et al., 2005), CXCL13 and its receptor CXCR5 (Amft et al.,
2001) and likely other constitutive chemokines for lymphoid aggrega-
tion and organisation in the synovial sublining. In essence, they are
not only trainees in the inflammatory boot camp, but they also train
immune cells to establish synovitis.
Lesson One: Survive and Spread Cell proliferation and cell death are
crucial for developmental and homeostatic processes. In recent years,
the range of possible modes of cell death has dramatically expanded.
The two most important modes are apoptosis and necrosis. Apoptosis
is characterised by a regulated deconstruction of the cell, resulting in
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nuclear condensation and fragmentation, followed by scattering of the
cell (Mariño et al., 2014). On the other hand, necrosis is marked by
cellular leakage and swelling (Vanden Berghe et al., 2014). These
two forms cannot be distinctively separated, since other forms of cell
death such as necroptosis, a more regulated form of necrosis, have
been discovered (Vanden Berghe et al., 2014).
The apoptotic cell death is induced by either extrinsic or intrinsic fac-
tors (Figure 2.5). The CD95 (Fas) ligand binds to its receptor, CD95,
and activates several proteins, which in turn cleave the aspartat pro-
tease pro-caspase 8 into its active form. In a similar mechanism TNF
binds to the TNF-related apoptosis-inducing ligand (TRAIL) receptor,
which also activates caspase 8. Caspase 8 triggers and orchestrates fur-
ther caspases and causes the mitochondrial outer membrane permeabi-
lization (MOMP). The mitochondrial leakage releases cytochrome C,
which is responsible for the assembly of caspase 9 to the apoptosome.
MOMP is directly induced by cellular stress, e.g. nitroxic radicals or
radiation.
Though fibroblast-like synoviocytes in RA are under inflammatory, hy-
poxic and nitrogenic stress, they show a reduced sensitivity to apop-
tosis. This is because chronic inflammation, in particular, changes
behaviour of SF in the intimal synovial lining to a tumorous charac-
ter:
Bcl-2 and mcl-2 expression increases, which serves as an anti-apoptotic
signal (Matsumoto et al., 1996; Perlman et al., 2000; Liu et
al., 2005).
CD95/Fas is widely expressed in RA synovia, although SF show a
resistance to CD95 treatment (Imamura et al., 1998). This resis-
tance continues in vitro (Meinecke et al., 2007).
P53 undergoes somatic mutation similar to many tumours (Firestein
et al., 1997; Yamanishi et al., 2002).
In sum, somatic mutation of genetic content and epigenetic modu-
lation of gene expression might explain certain responses by inflam-
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matory signals in rheumatoid arthritis synovial fibroblasts (RASF),
different from osteoarthritis synovial fibroblasts (OASF) or healthy
control samples. Their resistance to apoptosis also changes the prolif-
erative behaviour of SF. The morphological hallmark of this behaviour
is the pannus.
Lesson Two: Invade and Infiltrate The pannus can be seen as the
forefront of invasion into neighbouring structures, such as cartilage
and bone. Fibroblast-like synoviocytes evade contact inhibition and
substantially invade and destroy cartilage (Müller-Ladner et al.,
1996), even beyond distances similar to metastasation (Lefèvre et
al., 2009). The degree of fibroblast invasiveness correlates with the ra-
diographic stage of joint destruction (Tolboom et al., 2005). There-
fore, alteration of the invasive character of RASF is another step in
the pathogenesis of RA.
Lesson Three: Destroy and Decay SF are crucial in the destruction of
joint cartilage, as they produce degrading matrix metalloproteinases
(MMP), of which
the secretable collagenases MMP-1, -8, -13;
the non-secretable membrane-anchored collagenases MMP-14 and -16
and
the stromelysins MMP-3 and -10
are mainly responsible for matrix degradation (Bartok et al., 2010;
McInnes et al., 2011; Firestein et al., 2012).
The secretion is triggered by cytokines including TNF𝛼, TGF𝛽 or
IL-1𝛽. IL-1𝛽 is the strongest inducer of MMP secretion via activation
of MAPK/AP-1, STAT and NF𝜅B pathways (Li et al., 2001; Meng-
shol et al., 2000; Brauchle et al., 2000; Barchowsky et al., 2000).
Therefore, the reduction of MMP secretion by SF should be a main
therapeutic target in RA. This might be achieved by a reduced se-
cretion of these cytokines or by a reduced activation of intracellular
signaling.
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Figure 2.5: The extrinsic and intrinsic mechanism of apoptosis. AIF denotes apoptosis-inducing
factor, APAF-1 apoptotic protease-activating factor1, BAK BCL-2 antagonist or killer, BAX BCL-2-
associated X protein, BCL-2 b-cell lymphoma protein 2, BH3 BCL-2 homology 3, BID BH3-interacting
domain death agonist, CD95 cluster of differentiation 95 or Fas receptor, DISC death-inducing
signalling complex, DNA deoxyribonucleic acid, EndoG endonuclease G, FADD FAS-associated
death domain, JNK JUN N-terminal kinase, MLMP lysosomal membrane permeabilization, MOMP
mitochondrial outer membrane permeabilization , NIX NIP3-like protein X, PUMA and NOXA p53
upregulated modulator of apoptosis, RIP receptor-interacting protein, ROS reactive oxygen species,
TNFR1 tumour necrosis factor receptor 1, TRADD TNFR1-associated death domain and TRAILR
TNF-related apoptosis inducing ligand receptor (Mariño et al., 2014).
2.3.2 The Inner Ambition: MAPK, CREB and Their Role in
Survival, Invasion and Destruction
MAPK In RA fibroblasts, the intracellular system of mitogen-activated
protein kinases is the most widely studied signaling pathway and vi-
tal for the secretion of MMPs and inflammatory cytokines (Bottini
et al., 2013). This highly conserved system consists of three distinct,
but not completely separate, MAPK pathways: ERK, p38 and JNK
(Figure 2.6) (Widmann et al., 1999).
After four levels of phosphorylation and activation of distinct kinases,
phospholipases and cytosceletal proteins (Johnson et al., 2002), the
kinases ERK, p38 and JNK enter the nucleus and activate transcrip-
tion factors. By this means of shaping gene expression, ERK is mainly
associated with cell proliferation and differentiation, whereas p38 and
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JNK are involved in the cellular response to various forms of stress
(Johnson et al., 2002). All three signaling pathways show higher ac-
tivity in RASF compared to OASF (Han et al., 1999; Schett et al.,
2000), which might result from chronic inflammation and stress, but
also from epigenetic changes in the genes of these proteins (Bottini
et al., 2013).
ERK Signaling At least in part, ERK is activated by TNF in RASF,
promotes proliferation and apoptosis (Görtz et al., 2005). Further-
more, activation of ERK fosters the secretion of IL-6, IL-8 and MMP-3
(Calmon-Hamaty et al., 2011). The ERK pathway has also been
shown to mediate IL-6 secretion after IL-1 stimulation of RASF (Dou
et al., 2013).
JNK Signaling MMP secretion is mainly regulated by the MKK7-
JNK-AP1 signaling axis (Bartok et al., 2010). Upon IL-1 stimu-
lation, the kinase MKK7 is able to phosphorylate JNK, which itself
activates c-JUN. Phopshorylated c-JUN binds to the FBJ murine os-
teosarcoma viral oncogene homolog (FOS) and complements the AP1
transcription factor complex, which binds to specific MMP gene loci
in RASF (Bottini et al., 2013). This is the reason why the secre-
tion of the important MMP-1, -3 and -13 are dependent on the active
JNK pathway (Han et al., 2001). JNK shows a higher activation
upon stimulation with IL-1 in RASF, compared to OASF (Han et al.,
1999).
p38 Signaling In addition to JNK, p38 is the pivotal regulator for
fibroblast aggressiveness. Blocking the p38 pathway in RASF has
revealed their involvement in MMP-1 and -3 production as well as IL-
6 and -8 secretion upon IL-1 stimulation (Westra et al., 2004; Inoue
et al., 2005, 2006). The therapy of RA with p38 inhibitors did not show
greater benefit compared with current regimens (Damjanov et al.,
2009; Genovese et al., 2011). This proves the complex and redundant
role of the p38 signaling pathway, while heterotropic and even opposed
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Figure 2.6: Overview of the MAPK system. ASK 1 denotes apoptosis signal-regulating kinase 1,
BMK big MAPK kinase, DLK1 delta-like 1, ERK extracellular-signal regulated kinase, GPCR G
protein-coupled receptor, JNK c-Jun N-terminal kinase, MAPK mitogen-activated protein kinase,
MAPKK mitogen-activated protein kinase kinase, MAPKKK mitogen-activated protein kinase kinase
kinase, MEK MAPK/ERK kinase, MEKK MAPK/ERK kinase kinase, MKK p38 MAPK kinase, MLK
mixed-lineage kinase, Mos V-mos Moloney murine sarcoma viral oncogene homolog, p38 protein 38,
Raf rat fibrosarcoma kinase, SAPK stress-activated protein kinase, TAK TGF𝛽-activated kinase and
Tpl2 tumor progression locus 2 (Cell Signaling Technology, 2010).
function in fibroblasts and leukocytes have to be considered (McInnes
et al., 2011; Bottini et al., 2013).
CREB pathway Another mechanism of altering gene expression by
extracellular stimuli is the cAMP-responsive element binding protein
(CREB). Upon stimulation by catecholamines, intracellular cyclic AMP
increases and protein kinase A is activated, which then phosphorylates
CREB (Gonzalez et al., 1989). The MAPK ERK2 and p38 also are
able to enhance CREB activity through the activation of mitogen- and
stress-activated protein kinase MSK (Deak et al., 1998; Tan et al.,
1996) and pp90(RSK) family RSK2 (Xing et al., 1996). As a result,
these MAPK and CREB are able to induce IL-6 secretion after IL-
1 stimulation in RASF (Dou et al., 2013). Another mechanism of
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CREB activation is the Ca2+ influx mediated by Ca2+/calmodulin-
dependent kinases (Dash et al., 1991).
The active CREB binds the CREB-binding protein in the nucleus
(Chrivia et al., 1993) and changes the expression of hundreds of genes
affecting signaling, metabolism and proliferation (Impey et al., 2004).
Particularly in RASF, evidence of the role of the CREB pathway is
rare. For example, phosphorylated CREB has been found to be higher
in RASF than in OASF (Pérez-García et al., 2011) and to be func-
tionally involved in the IL-6 secretion by RASF (Ishizu et al., 2010).
2.3.3 Conclusion: Synoviocytes as a Therapeutic Target
The current success of biologicals in the treatment of RA proves that
the modulation of the immunological process in rheumatoid arthritis is
crucial for breaking the inflammatory cycle in the joint, but this might
be not sufficient. Since synovial fibroblasts in RA show independent
aggressive behaviour apart from immunological regulation, targeting
them might be an effective adjuvant therapy. For example, Lee et al.
(Lee et al., 2007) showed the anti-inflammatory effect of a novel non-
immunological antibody against cadherin-11, an important building
block for the synovial layer and regulator of inflammatory responses
in RASF (Chang et al., 2011). As Bottini et al. (Bottini et al.,
2013) have noted, combination therapies with dual suppression both
immunological cells and fibroblasts pave the way for innovative treat-
ments. As one possibility, cannabinoids might offer such promising
combinations.
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Figure 2.7: Overview of the PKA-CREB-Pathway. AC denotes adenylyl cyclase, cAMP cyclic AMP,
CRE/CREB cAMP-responsive element (CRE)-binding protein, GPCR G protein-coupled receptors,
PKA protein kinase A and R regulatory subunits of PKA (Altarejos et al., 2011).
2.4 The Endocannabinoid System
2.4.1 The Cannabinoid Receptors
The Cannabinoid Receptors Cannabinoid Receptors CB1 and CB2 are
G-protein coupled receptors, which, upon activation, induce the sec-
ond messenger Gi/o protein to inhibit adenylate cyclase and to stimu-
late MAP-Kinases. (Alexander et al., 2011; Pertwee et al., 2010).
Cannabis research has been undertaken since the 19th century, when
the psychoactive ingredients of cannabis were studied with interest
(Iversen, 1999). The chemical synthesis of 𝛥9-tetrahydrocannabinol
by Gaoni and Mechoulam was the gateway to serious scientific inves-
tigation of the cannabinoids (Mechoulam et al., 1965).
Cannabis sativa contains over 60 substances, from which 𝛥9-tetra-
hydrocannabinol are mostly responsible for psychoactivity (Mechou-
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lam et al., 1970). The synthesis of 𝛥9-tetrahydrocannabinol ana-
logues allowed for research in the molecular structure and physiologi-
cal function of cannabinoids, e.g. in psychomotoric vigilance or body
temperature. This research eventually led to the relevation of the until-
then orphan receptor SKR6 to be the G-protein-coupled cannabinoid
CB1 receptor (Gérard et al., 1990).
Subsequently, a second G-protein coupled cannabinoid receptor, CB2,
was identified in the human promyelocytic leukaemic cell line HL 60
(Munro et al., 1993).
Non-Cannabinoid-Receptors: GPR55 and TRPV Besides the classi-
cal CB-1 and -2 receptor, the endocannabinoid system also interact
with the G protein-coupled receptor 55 (GPR55) and the transient
receptor potential channels (TRP) such as for the vanilloid family
TRPV (Alexander et al., 2011). GPR55 belongs to the GPCR su-
perfamily like CB1 and CB2, but transmits its signal to Gq, G12 or G13
(Ryberg et al., 2007; Sharir et al., 2010; Alexander et al., 2011),
which generally activates downstream proteins like the GTPase Ras
homolog gene family member A (RhoA) or phospholipase C. GPR55
has been reported to be involved in inflammatory pain and bone phys-
iology (Sharir et al., 2010).
The TRPV receptors are divided into the two groups of thermosen-
sitive non-selective cation channels TRPV1-4 and the calcium chan-
nels TRPV5 and 6 (Alexander et al., 2011). Classical functions
of TRPV include pain generation by heat (Starowicz et al., 2007)
and regulation of the innate immune system, such as phagocytosis in
macrophages (Link et al., 2010).
2.4.2 The Endogenous Ligands
The identification of receptors for tetrahydrocannabinol suggested
endogenous ligands for these receptors. So far, two major endocannabi-
noids have been identified: 2-arachidonylethanolamide (anandamide
or AEA) and 2-arachidonylglycerol (2-AG) (Devane et al., 1992;Me-
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choulam et al., 1995). In general, these two agonists and the CB1 and
CB2 receptor constitute the endogenous cannabinoid system (ECS).
2.4.3 General Effects
Since the discovery of AEA and 2-AG, the ECS has revealed to be
a highly complex lipid system with distinct effects on neuronal and
non-neuronal cells.
Generally, the CB1 receptor is mainly expressed in the central nervous
system, whereas the CB2 receptor is widely expressed in immune cells
(Pertwee et al., 2010). Changes in the activity of the endocannabi-
noid system have been shown to correlate with
neuronal conditions: pain and inflammation (Hohmann et al., 2006;
Jhaveri et al., 2007); neurological and neuropsychiatric condi-
tions (Bisogno et al., 2007).
non-neuronal conditions: immunological (autoimmune and allergic) dis-
orders (Oka et al., 2006); cancer (Bifulco et al., 2007); and
gastrointestinal (Storr et al., 2007) and hepatic (Mallat et al.,
2007) disorders.
interconnected conditions: obesity, metabolic syndrome (Matias et
al., 2007) and cardiovascular disorders.
However, there have been contradictory results concerning the benefi-
cial or detrimental effects of the endocannabinoids in the same tissue
under a given pathological stress, which demonstrates the different
interactions of the endocannabinoid system and the complexity of reg-
ulation (Di Marzo et al., 2007; Pacher et al., 2006).
Considering effects on rheumatoid arthritis, evidence for a specific
mode of action is rare. However, adjacent research fields of inflamma-
tion and pain might provide some clue of the endocannabinoid influ-
ence on RA. Thus, this introduction only presents the effect of endo-
cannabinoids on inflammation and inflammatory pain in neuronal and
non-neuronal systems.
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Neuronal Effects: Inflammation and Pain When stressed by inflam-
mation or irritants, levels of endocannabinoids in rodent skin, periph-
eral nerves and spinal cord are elevated (Oka et al., 2006). Neu-
ropathic pain also increases these levels (Mitrirattanakul et al.,
2006; Petrosino et al., 2007), where endocannabinoids serve as anal-
getic (Agarwal et al., 2007). These features lead to a recent interest
in the use of cannabinoids to treat multiple sclerosis.
Though less expressed in the brain, CB2 is upregulated in microglial
and glial cells in response to blood-brain barrier disruption or other
inflammatory conditions (Lunn et al., 2008).
Non-Neuronal Effects: Inflammation and Cancer In gastrointestinal
inflammation, the ECS is involved in visceral perception and gut motil-
ity, but also in inflammation and endothelial damage, since it ame-
liorates inflammation through CB1 (Di Marzo et al., 2006, 2007;
Massa et al., 2004; D’argenio et al., 2006). In the skin, the en-
docannabinoid system is able to alleviate contact dermatitis in mice
(Karsak et al., 2007).
Endocannabinoids exert anticarcinogenetic effects in a variety of tis-
sues through both CB1 and CB2 receptors by modulating a host of
different mechanisms such as mitosis, apoptosis, angiogenesis, migra-
tion and metastasis (Guzmán, 2003; Bifulco et al., 2007). Yet, CB1
antagonism with rimonabant also inhibits carcinogenesis (Sarnataro
et al., 2006).
2.4.4 Conclusion: Using Complexity
In conclusion, cannabinoids generally exert an anti-inflammatory ef-
fect and are likely to be up-regulated in inflamed tissues. However,
predictability of agonising or antagonising of the ECS in a given in-
flamed tissue seems to be very limited. Also, given the difference
between early and late inflammation and between murine and human
physiology, beneficial effects of endocannabinoids might differ greatly.
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2.5 Conclusion: Synergy is Energy
While the therapeutic outcome has significantly improved due to
biological treatment, current ambitions aim to combine conventional
therapeutics and to decrease cost intensity (Firestein et al., 2012;
O’Dell et al., 2013; Sokka et al., 2013). Instead of using single
treatments, the usage of synergic factors in a combined therapy might
be a powerful strategy to reduce dosage and adverse effects or to widen
the therapeutic spectrum of established drugs, but demands appropri-
ate selection of therapeutics. The different points of action of the
therapeutics and their interactions with each other have to be consid-
ered. Selection of the proper treatment for a particular patient will
be crucial to stay ahead of the forthcoming pressure on treatment
costs. There is increasing evidence that cannabinoid treatment might
be useful to be integrated in such a supportive strategy.
2.6 Purpose and Goal: From Pathogenesis to Treatment
Evidence of the influence of endocannabinoids on intracellular sig-
naling of the fibroblast-like synoviocytes and its consequences on pro-
liferation and cell death is still limited. However, this is crucial for
1. a further understanding of the pathogenic influence of the endo-
cannabinoids in RASF and its role in RA, and thus
2. the development of potential new or combined therapies with es-
tablished cannabinoid agonists or antagonists.
Therefore, this study investigated the influence of selective cannabi-
noid agonists and the endogenous agent anandamide on two of the
main mechanisms in fibroblasts, namely intracellular MAPK and CREB
signaling, which coordinate proliferation, cytokine secretion and apop-
tosis.
Materials and Methods
Table 3.1: Disposable Materials
Material Supplier
Culture flasks Corning, New York, USA
Multiflask BD Falcon, Plymouth, UK
Safe Lock Tubes Eppendorf, Hamburg, Germany
Table 3.2: Technical Devices
Material Supplier
Scepter™ Cell Counter Merck Millipore, Billerica, USA
iMark™ Microplate Reader (for Ab-
sorbance) Bio-Rad, Hercules, USA
ChemiDoc™ XRS+ Molecular Imager
Victor Multilabel Counter Perkin Elmer, Waltham, USA
Coulter EPICS XLMCL™ Beckmann Coulter, Brea, USA
29
30 3 Materials and Methods
Table 3.3: Agents and Stimulans
Material Supplier
Cannabinoids
Anadamide
Tocris, Bristol, UK
Am251
JTE
JNJ
CP47497
Hu210
Cytokines
TNF𝛼
Peprotech, Rocky Hills, USAInterleukin-1𝛽
Lipopolysaccharide
Table 3.4: Cell Acquisition and Culturing
Material Supplier
RPMI
Sigma, Deisenhofen, Germany
Amphotericin B 0.25mgmL−1
Bovine Serum Albumin
HEPES-Buffer 1mol
Fetal Calf Serum
Penicilline/Streptomycine
Trypsin
PBS
2-Mercaptoethanol
Ascorbic acid
Calcium
Ammonium chloride
Ammonium bicarbonate
DMSO
L-glutamine 200mmol Invitrogen, Carlsbad, USA
Dispase I Roche Diagnostics, Mannheim, Ger-
many
EDTA PAA Laboratories, Pasching, Austria
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Table 3.5: Intracellular Signaling
Material Supplier
Antibodies
Phospho-p44/42 - Erk1/2 on site
Thr202/Tyr204
Cell Signaling Technology, Danvers,
USA
Anti-p38 (phospho T180 + Y182) Anti-
body Abcam, Cambridge, UK
Anti-CREB (phospho S133) Antibody
Polyclonal Goat Anti-mouse Im-
munoglobuline HRP
Dako, Glastrup, Denmark
Pierce Goat Anti-Rabbit Poly-HRP Thermo Scientific, Waltham, USA
Washing, Blocking, and Develop-
ment
Triton 100X AppliChem, Darmstadt, Germany
Bovine serum albumin Sigma, Deisendorf, Germany3,3’,5,5’-Tetramethylbenzidine Tablet
1mg
1-Step™ Ultra TMB-ELISA Thermo Scientific, Waltham, USA
Proteome Profilers
Proteome Profiler Human Phospho-
Kinase Array Kit R&D Systems, Minneapolis, USA
Proteome Profiler Human Cytokine Ar-
ray Kit
Amersham ECL™ Western Blotting
Reagents
GE Healthcare, Chalfont St Giles, UK
Table 3.6: Cell Viability and Cytotoxicity
Material Supplier
Proteome Profiler Apoptosis Array Kit R&D Systems, Minneapolis, USA
LDH Cytotoxicity Detection Kit ClonTech, Mountain View, USA
Apoptosis Detection Kit BD Biosciences, San Jose, USALysis Buffer 6
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3.1 Patients
Cells were acquired from a total of 24 patients with long-term rheuma-
toid arthritis according to the ACR criteria (Arnett et al., 1988) and
22 patients with osteoarthritis. Every patient underwent an elective
operation for knee replacement. All subjects gave informed consent
to participate in this study. The study was approved by the Ethics
Committee of the University of Regensburg. Relevant clinical data
and anti-inflammatory drugs are listed in Table 3.7.
Table 3.7: Characteristics of Patients. CRP denotes c-reactive protein, NSAID nonsteroidal anti-
inflammatory drug and DMARD disease-modifying antirheumatic drug
OA RA
Age [years] 71 ± 9.4 61 ± 11.3
Sex [numbers of males/females] 10/12 3/21
CRP [mg/L] 4.1 ± 4.6 9.3 ± 9.9
Usage of NSAID [No.] 19 22
Usage of prednisolone [No.] 1 20
Daily dosis of prednisolone [mean
± standard error in mg]
N/A 12.1 ± 6.3
Usage of methotrexate N/A 9
Usage of DMARD N/A 13
Usage of biologicals N/A 3
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3.2 Cell Culture
3.2.1 Tissue Preparation
Tissue was extracted directly after opening of the articular capsule
and stored in transportation medium, which consists of RPMI-1640
with 25mm HEPES, 5% Fetal Calf Serum, 1 % penicilline/strepto-
mycin, 30 µm 2-mercaptoethanol, 0.57mm ascorbine acid and 1.3mm
calcium.
Tissue samples were cut into 9 cm2 sections and detached from fat tis-
sue or highly vascularised parts. A portion of the samples was stored at
−80 ∘C, and the remaining samples were used for cell culture. For ex-
traction, the tissue samples were smashed and solubilised with Dispase
I for 1 h at 37 ∘C on a rocking platform shaker. The suspension was fil-
tered with 70µm of pore size and centrifuged for 10min at 300·g. The
pellet was resuspended, incubated with erythrolysis buffer (20.7mg
ammonium chloride, 1.97mg ammonium bicarbonate, 0.09mg EDTA,
1L H2O) for 5min and re-centrifuged for 10min at 300·g. The final
pellet was resuspended with RPMI-Medium containing 10 % FCS and
1𝑥105 cells were seeded in 75 cm2 culture flasks. The culture medium
was changed on the second day.
3.2.2 Cryopreservation and Thawing
For long-term storage, cells were cryo-conserved in fluid nitrogen at
−196 ∘C. Prior to this, cells were
1. detached with 2.5mL EDTA/Trypsin solution for 5min,
2. centrifuged at 300·g,
3. resuspended in a protection solution against cristallisation and cell
lysis (cell culture medium with 40 % FCS and 10 % DMSO), and
4. frozen stepwise, first down to −80 ∘C for 48 h, then to −196 ∘C.
Prior to culture, frozen cells were
1. quickly thawed at 37 ∘C,
2. transfered to 10mL fresh pre-warmed cell culture medium,
3. centrifuged at 300·g for 10min,
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4. resuspended in fresh pre-warmed medium and
5. finally transferred 1× 105 in 75 cm2 culture flask.
The culture medium was changed on the second day.
3.2.3 Cell Culturing
Cells were cultured in culture medium (RPMI-1640 with 1 % HEPES,
5 % Fetal Calf Serum, 1 % penicillin/streptomycin, 2 % L-glutamine,
0.1 % amphotericin B) at a constant temperature of 37 ∘C and 2 %
O2/5 % CO2 in a fully saturated environment in 175 cm2 and 75 cm2
culture flasks.
Cells were split 1:2 or 1:3 with 10 % trypsin/-PBS solution every week
according to their confluence. Only passages 2 to 7 were used for the
experiments. This was important since macrophage-like synoviocytes
are still present in the first cell culture passage and fibroblast-like
synoviocytes degenerate from the 7th passage onwards (Rosengren
et al., 2007).
3.3 Detection of Intracelluar Activation of ERK, p38, c-JUN
and CREB
Cells were transferred into 96-well plates with 10,000 cells/well. Cells
were starved for 24 h in serum-free medium to reduce basal phospho-
rylation. Thereafter, they were incubated with agents described in
Table 3.3. For the quantification of intracellular posphorylated ki-
nases, a cell-based ELISA was performed according to the following
procedure:
1. Fixation of cells by formalin (4 %)-PBS solution for 20min
2. Washing twice with Washing Buffer (PBS, Triton 0.1 %) for 10min
3. Incubation with Blocking Buffer (Washing Buffer, 1 % BSA) for
1 h.
4. Washing once as described in step 2.
5. Incubation of the first antibody overnight at 4 ∘C.
6. Washing twice as described in step 2.
7. Incubation of the second antibody for 1 h.
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8. Washing twice as described in step 2.
9. Development with TMB
10. Stop reaction with 2m NaSO4.
11. Absorbance was recorded at 450 nm with an iMark™ Microplate
Reader.
3.4 LDH Cytoxicity Detection
In late apoptosis and necrosis, cell membrane leakage releases in-
tracellular lactate dehydrogenase. After stimulation in serum-free
medium, the supernatant was transferred to a separate 96-well plate
and incubated with the Cytotoxicity Detection Kit (ClonTech, USA)
acoording to the retailer instructions. Measurement of absorbance was
performed at 490 nm with an iMark™ Microplate Reader.
3.5 Flow Cytometry with Annexin V and Propidium Iodide
Annexin V binds to extracellular phospholipid phosphatidylserine,
whose translocation from the inner to the outer plasma membrane
leaflet occurs during early apoptosis. In late apoptosis and necrosis,
membrane stability deteriorates, so that membrane leakage leads to
DNA discharge. Cytoplasmatic DNA is detected by propidium iodide
(PI).
Cells were detached with Accutase™ and transferred into 1.5mL Ep-
pendorf Safe Lock Tubes. Cells were incubated with FITC and 7-
AAD for 15 min at room temperature. Data acqusition was performed
with the flow cytometer Coulter EPICS XLMCL™. Data output was
analysed with FlowJo™ (FlowJo LLC, Oregon, USA, V.10). A sub-
population of fibroblasts was set to exclude cell detritus.
3.6 Proteome Profiler: Human Phosphokinase, Apoptosis and
Human Cytokine Kit
Cells were cultured in 75 cm2 culture flask and starved in serum-free
medium for 48 h in normoxic or hypoxic (1 % O2) conditions. Cells
were stimulated as described below, in normoxic or hypoxic environ-
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ments, respectively. Cells were washed twice with Dulbecco’s PBS,
solubilised with Lysis Buffer 6, and immediately stored at −25 ∘C.
The Human Phospho-Kinase Kit (R&D Systems, Minneapolis, USA)
measures the relative level of phosphorylation of 45 different intracel-
lular kinases. The Human Apoptosis Array Kit measures the expres-
sion of 35 apoptosis-related proteins. Both Kits use specific antibod-
ies attached to nitrocellulose slides and are performed as a sandwich
enzyme-linked immunosorbent assay ELISA. Preparation and detec-
tion of samples were performed according to the instructions provided
by the manufacturer. Chemiluminiscence was developed using the
reagents included in the kit as well as Amersham ECL™ Western
Blotting Reagents. Plots were read with a BioRad ChemiDoc™ XRS+
Molecular Imager, using a defined frame of 13.5 cm x 10 cm and a bin-
ning of 3x3 to increase sensitivity without any filtering. Analysis of
relative dot density of the photographs was performed with Image-
Lab™ (Bio-Lab Laboratories, V. 4.0.1), using the digital mean pixel
intensity of the photographs for each point on the slide
3.7 Statistical Analysis
Statistical analysis and plotting were performed with SPSS (V.22,
IBM™) and SigmaPlot™ software (V.13, Systat Software Inc.). Each
statistical analysis was performed non-parametrically with the Mann-
Whitney Rank-Sum test. A p-value <0.05 was the significance level.
Results and Discussion
4.1 The Predominance of ERK
The Proteome Profiler showed the relative phosphorylated levels of
most intracellular signaling proteins and revealead ERK to be the
most active MAPK in unstimulated RASF, followed by p38, pan-JNK,
c-Jun and CREB in normoxia (Figure 4.1). In hypoxia, expression lev-
els changed minimally, whereas pan-JNK was significantly suppressed
(ibid.).
Figure 4.1: Rheumatoid arthritis synovial fibroblasts were incubated in normoxia (n=4) or hypoxia
(n=5) for 24 h, lysed and incubated on Proteome Profiler™ membranes. A. Numerical expression of
MAP-kinases and CREB on the Proteome Profiler™. ERK denotes extracellular-signal regulated kinase,
p38 protein 38 MAPK, Pan-JNK the total amount of c-Jun N-terminal kinase, c-JUN as member
of the Jun transcription factors and CREB cAMP-responsive element binding protein. B. Actual
Proteome Profiler™ slides after 15min in normoxia (left) and hypoxia (right). The numbers 1-5 refer
to the set of dots left to them and denote the MAPK described in a.*= p<0.05.
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The stimulation of RASF and OASF for 15min showed a significantly
higher phosphorylation of ERK, p38, CREB and c-JUN in normoxic
and hypoxic environment (Figure 4.2). In RASF but not in OASF, the
normoxic and hypoxic ERK phosphorylation was significantly higher
in response to TNF (10 nmL−1) than to IL-1𝛽 (1 nmL−1), whereas the
normoxic phophorylation of p38 was significantly higher after stimula-
tion with IL-1𝛽. In contrast, TNF𝛼 activated c-JUN more effectively
in OASF compared to RASF under hypoxic conditions (Figure 4.2).
4.2 The Antagonistic Effects of CB1 and CB2 on p38
Samples were pre-incubated with CB1 and CB2 agonists for 5 h and
then stimulated with the pro-inflammatory cytokines TNF𝛼, IL-1𝛽
and Lipopolysaccharide (LPS) for 15min. Positive control samples
were stimulated only with the cytokines.
Compared to the positive control samples, CB1 and CB2 agonists
showed significantly different inhibitory and stimulatory patterns on
intracellular signaling in normoxia and hypoxia (Figure 4.3 and 4.4).
In normoxia, the CB2 agonist GP1a attenuated the IL-1𝛽-induced
phosphorylation of the stress-related kinases p38 and CREB. In OASF,
the CB2 agonist repressed TNF𝛼 stimulation of p38 and the LPS-
induced phosphorylation of p38 and CREB. In hypoxia, the LPS-
induced stimulation of ERK was repressed by CB2 agonism only in
RASF. In OASF, GP1a more extensively repressed TNF𝛼-induced
stimulation of p38 as well as the TNF𝛼- and IL-1𝛽-induced stimula-
tion of CREB. The MAPK c-JUN was similarly repressed by CB1 and
CB2 in both OASF and RASF after TNF𝛼, whereas only the CB2
agonist reduced c-Jun activation after IL-1𝛽 an LPS stimulation both
in RASF and OASF, compared to the positive control samples.
In contrast, samples preincubated with CB1 agonist showed slightly
(in OASF) and significantly (in RASF) higher p38 phosphorylation
after IL-1𝛽 stimulation, compared to the positive control samples in
normoxia and hypoxia (Figure 4.3 and 4.4).
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Figure 4.2: Rheumatoid arthritis synovial fibroblast (RASF, n=5, n=2 for c-Jun) and Osteoarthritis
synovial fibroblasts (OASF, n=5, n=2 for c-Jun) were stimulated with Tumor Necrosis Factor 𝛼
(TNF𝛼, 10 ngmL−1), Interleukin-1 (IL-1𝛽, 1 ngmL−1) or Lipopolysaccharide (LPS, 10 µgmL−1) for
15min. The level of phosphorylation of extracellular-signal regulated kinase (ERK), p38 MAPK (p38),
cAMP-responsive element binding protein (CREB) and c-Jun protein (c-JUN) was measured with
ELISA. Absorbance of the samples is given in percentage of median of the control samples (NEG)
on each plate. Samples were compared to the negative control samples: *= p<0.05, **= p<0.01,
***= p<0.001.
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Figure 4.3: Rheumatoid arthritis synovial fibroblast (RASF, n=5) and osteoarthritis synovial
fibroblasts (OASF, n=5) were pre-incubated for 5 h in normoxia with CB1 agonist CP 47,497
(CB1, 1× 10−6 m), CB2 agonist GP1a (CB2, 1× 10−7 m), anandamide (A-6, 1× 10−6 m and A-
10, 1× 10−10 m), or fatty acid amide hydrolase JNJ (JNJ, 1× 10−7 m), and thereafter stimulated with
Tumor Necrosis Factor 𝛼 (TNF, 10 ngmL−1), Interleukin-1 (IL-1, 1 ngmL−1) or Lipopolysaccharide
(LPS, 10 µgmL−1). Positive control samples are denoted as their stimulant (TNF, IL-1 or LPS).
The level of phosphorylation of extracellular-signal regulated kinase (ERK), p38 MAPK (p38) and
cAMP-responsive element binding protein (CREB) was measured with ELISA. Absorbance of the
samples is given in percentage of median of negative control samples on each plate. Samples were
compared to positive control samples. *= p<0.05, **= p<0.01, ***= p<0.001, if not mentioned
otherwise.
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Figure 4.4: Rheumatoid arthritis synovial fibroblast (RASF, n=5) and osteoarthritis synovial fibrob-
lasts (OASF, n=5) were pre-incubated for 5 h in hypoxia with CB1 agonist CP 47,497 (CB1, 1× 10−6 m),
CB2 agonist GP1a (CB2, 1× 10−7 m), anandamide (A-6, 1× 10−6 m and A-10, 1× 10−10 m), or fatty
acid amide hydrolase JNJ (JNJ, 1× 10−7 m), and thereafter stimulated with Tumor Necrosis Factor 𝛼
(TNF, 10 ngmL−1), Interleukin-1 (IL-1, 1 ngmL−1) or Lipopolysaccharide (LPS, 10 µgmL−1). Positive
control samples are denoted as their stimulant (TNF, IL-1 or LPS). The level of phosphorylation of
extracellular-signal regulated kinase (ERK), p38 MAPK (p38), cAMP-responsive element binding
protein (CREB) and c-Jun protein (c-JUN) was measured with ELISA. Absorbance of the samples is
given in percentage of median of negative control samples on each plate. Samples were compared to
positive control samples. *= p<0.05, **= p<0.01, ***= p<0.001, if not mentioned otherwise.
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4.3 The Antagonistic Effects of Anandamide
Samples were pre-incubated with anandamide for 5 h and then stim-
ulated with the pro-inflammatory cytokines TNF𝛼, IL-1𝛽 and Lipo-
polysaccharide for 15min.
In comparison to the positive control samples, anandamide attenu-
ated the cytokine-induced phosphorylation of MAPK at low concen-
tration and increased stimulation at high concentration. Preliminary
Proteome Profiler™ experiments revealed a significant decrease in the
expression of phosphorylated ERK and pan-JNK after incubation with
1× 10−7 m AEA in RASF under hypoxia (Figure 4.5). In further ex-
periments using RASF, 1× 10−10 m AEA repressed the IL-1𝛽- and
LPS-induced phosphorylation of p38 in normoxia, and of ERK in hy-
poxia. In OASF, pre-incubation with 1× 10−10 m AEA decreased
phosphorylation of ERK, p38 and CREB by LPS in normoxia (Fig-
ures 4.3 and 4.4). Anandamide at 1× 10−6 m significantly increased
phosphorylation levels of the stress-related kinases p38 and CREB
upon TNF𝛼, IL-1𝛽 stimulation in OASF and RASF under normoxia,
while it enhanced LPS-induced stimulation only in RASF. In hypoxia,
however, it increased levels of activated p38 in RASF after incuba-
tion with TNF𝛼 and IL-1𝛽 and in OASF only after incubation with
TNF𝛼 (Figures 4.3 and 4.4). Furthermore, AEA enhanced IL-1𝛽- and
LPS-stimulated CREB activation only in RASF (Figure 4.4).
4.3.1 Blocking the Recycling of AEA with JNJ Decreased
MAPK Phosphorylation
JNJ-1661010 (JNJ) is a selective inhibitor of intracellular fatty amide
acid hydrolase (FAAH), which leads to increased intracellular levels of
anandamide. Samples were pre-incubated with JNJ for 5 h and then
stimulated with the pro-inflammatory cytokines TNF𝛼, IL-1𝛽 and Li-
popolysaccharide (LPS) for 15min. Experiments with human and
rat brain cells showed JNJ to have an IC(50) of 12 nmol on human
FAAH with a twofold increase of intracellular anandamide at maxi-
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mum (Karbarz et al., 2009). A JNJ dose of 1× 10−7 m was used
to guarantee a maximal inhibition of intracellular FAAH. In compari-
son to the positive control samples, JNJ exerts an inhibitory effect on
MAPK phosphorylation (Figures 4.3 and 4.4). In RASF, FAAH inhi-
bition decreased TNF𝛼-, IL-1𝛽- and LPS-induced phosphorylation of
p38 in normoxia and LPS-induced MAPK activation in hypoxia. JNJ
decreased activation levels of CREB in RASF and OASF after IL-1𝛽
and LPS stimulation, both in normoxia and hypoxia. In OASF, JNJ
attenuated LPS-stimulated levels of ERK and CREB in normoxia and
TNF𝛼-, IL-1𝛽- and LPS-induced CREB activation in hypoxia.
4.3.2 Repression of Downstream Proteins
The Proteome Profiler also showed anandamide to significantly re-
press the expression of unstimulated 90 kDa Ribosomal S6 Kinase
(RSK) and stimulated Mitogen- and Stress-Activated Protein Kinase
(MSK) in hypoxic RASF (Figure 4.5). These two proteins are acti-
vated by MAPK ERK and p38 and establish a crosstalk between the
MAPK and CREB pathway.
44 4 Results and Discussion
Figure 4.5: Rheumatoid arthritis synovial fibroblast (RASF) were pre-treated with anandamide
(AEA, 1× 10−7 m) for 5 h in normoxia (n=4) or hypoxia (n=5) and subsequently stimulated with
TNF𝛼 (TNF, 10 ngmL−1). Samples were lysed and incubated on the Proteome Profiler™ slides.
Results are given as mean pixel intensities of respective spots of the kinases on the slides after
development for 5min. ERK denotes extracellular-signal regulated kinase, p38 protein 38 MAPK,
pan-JNK the total amount of c-Jun N-terminal kinase, c-Jun a member of Jun transcription factors,
MSK mitogen- and stress-activated protein kinase and RSK 90 kDa ribosomal S6 kinase. *= p<0.05,
**= p<0.01, ***= p<0.001, vs. negative control sample (CTRL). o= p<0.05, oo= p<0.01, vs. positive
control samples (TNF).
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4.4 Conclusion: The Activation Pattern of AEA Resembled
CB1 and CB2
High concentrations of AEA generally resembled the increase of phos-
phorylation by the CB1 agonist CP 47,497, such as in p38 after IL-1𝛽
incubation. However, at low concentrations, it attenuated MAPK sig-
naling like the CB2 agonist GP1a, such as p38 in RASF after incuba-
tion with IL-1𝛽 or in OASF after incubation with TNF𝛼 (Figure 4.3).
CB2 receptors are largely distributed and active peripherally in im-
mune cells and are known to take part in the immunomodulation dur-
ing the inflammation process. In an inflammatory environment, CB2
receptors are slightly up-regulated in RASF after stimulation with
TNF𝛼, IL-1𝛽 or LPS, compared to OASF (Gui et al., 2014). Selec-
tive CB2 agonists attenuated IL-1𝛽-induced p38 and ERK activation
in synovial fibroblasts (Gui et al., 2014) and TNF𝛼-induced activa-
tion of ERK1/2, p38 and JNK in smooth muscle cells (Rajesh et al.,
2008).
The present studies were consistent with these results and furthermore
showed for the first time that the endogenous agonist anandamide
demonstrated the same anti-inflammatory CB2-dependent pattern at
low concentrations, whereas at high concentrations, it increased phos-
phorylation, likely through a CB1-dependent mechanism or through
TRPV1 channels. TRPV1 channels are non-selective cation channels.
As a consequence, not only intracellular phosphorylation but also mem-
brane depolarisation and calcium homeostasis might be involved in the
in vivo activation of SF by AEA.
Furthermore, the present studies showed a different suppression and
activation pattern of MAP kinases in synovial fibroblasts under nor-
moxia and hypoxia. This insight might give some warranties against
possible therapeutic interventions with cannabinoids in RA, since their
effects might depend on the local oxygen concentration.
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4.5 Activation of MAPKMainly by CB1 in Rheumatoid Arthri-
tis Synovial Fibroblasts
4.5.1 Rheumatoid Arthritis Synovial Fibroblasts Are More
Prone to Stimulation
After 30min of incubation with CB1 agonist CP 47,497, CB2 agonist
GP1a or AEA under normoxia, phosphorylation of ERK were signifi-
cantly increased in RASF compared to OASF (Figure 4.6). In hypoxia,
CB1 agonism, CB2 agonism and AEA activated p38 and CREB only
in RASF and not in OASF, with the exception of the normoxic acti-
vation of CREB by AEA at 1× 10−8 m. Also in RASF and not in
OASF, ERK activation by AEA and GP1a was significantly increased
under normoxia compared to hypoxia (Figure 4.6).
4.5.2 The CB2 Agonist Activated ERK and CREB only in
Rheumatoid Arthritis Synovial Fibroblasts
When compared to the negative control samples, the CB2 agonist
GP1a induced a significant ERK and CREB activation only in RASF
(Figure 4.6). In addition, the ERK phosphorylation by AEA was
significant lower after pre-incubation with the inverse CB2 agonist
JTE-907 than without pre-incubation, whereas CREB activity after
stimulation by AEA did not change with or without pretreatment
with JTE-907 (Figure 4.7). Generally in OASF, pretreatment with
JTE-907 did not change the activation levels of ERK, p38 or CREB
after stimulation with CB1, CB2 and AEA, compared to unpretreated
samples (Figure 4.7).
4.5.3 The CB2 Agonist and the FAAH Inhibitor JNJ Acti-
vated ERK but Suppressed p38
In comparison with the negative control samples, CB2 agonism and
FAAH inhibition suppressed p38 phosphorylation in both RASF and
OASF, while the CB1 agonist CP 49,497 and AEA activated p38 in
RASF under hypoxia. Pre-incubation with the CB1 inverse agonist
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Figure 4.6: Rheumatoid arthritis synovial fibroblast (RASF, n=3) and osteoarthritis synovial
fibroblasts (OASF, n=3) were incubated in normoxia or hypoxia with CB1 agonist CP 47,497
(CB1, 1× 10−6 m), CB2 agonist GP1a (CB2, 1× 10−7 m), inverse CB1 agonist Rimonabant (RIM,
1× 10−6 m), CB2 inverse agonist JTE-907 (JTE, 1× 10−7 m) as well as anandamide AEA (A-6,
1× 10−6 m, A-8, 1× 10−8 m or A-10,1× 10−10 m) or fatty acid amide hydrolase JNJ (JNJ, 1× 10−7 m).
The level of phosphorylation of extracellular-signal regulated kinase (ERK), p38 MAPK (p38) and
cAMP-responsive element binding protein (CREB) was measured with ELISA. Absorbance of the
samples is given in percentage of median of the control samples on each plate. *= p<0.05, **= p<0.01,
***= p<0.001, vs. negative control sample (NEG). o= p<0.05, oo= p<0.01, ooo= p<0.001, vs. OASF.
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Figure 4.7: Rheumatoid arthritis synovial fibroblast (RASF, n=3) and osteoarthritis synovial
fibroblasts (OASF, n=3) were first pretreated with the CB1 inverse agonist Rimonabant (RIM,
1× 10−6 m) or CB2 inverse agonist JTE-907 (JTE, 1× 10−7 m) and, subsequently, stimulated with
the CB1 agonist CP 47,497 (CB1, 1× 10−6 m), CB2 agonist GP1a (CB2, 1× 10−7 m) or anandamide
AEA (A-6, 1× 10−6 m). The level of phosphorylation of extracellular-signal regulated kinase (ERK),
p38 MAPK (p38) and cAMP-responsive element binding protein (CREB) was measured with ELISA.
Absorbance of the samples is given in percentage of median of the control samples (NEG) on each
plate. *= p<0.05, **= p<0.01, ***= p<0.001, vs. sample without pretreatment.
Rimonabant or CB2 inverse agonist JTE did not alter these activation
and suppression levels in p38 (Figure 4.7).
4.5.4 AEA and the CB1 Agonist Showed Broadest Activation
of MAPK
AEA (1× 10−6 m) and the CB1 agonist CP 47,497 demonstrated the
strongest stimulation of MAPK in OASF and RASF under hypoxia
and normoxia (Figure 4.6), compared to the negative control samples.
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The CB2 antagonist JTE-907 significantly reduced the activation of
ERK by AEA in normoxia (Figure 4.7). After activation by the CB1
agonist ACEA or CB2 agonist GP1a, ERK phosphorylation peaked at
3 h in RASF and at 4 h in OASF (Figure 4.8).
Figure 4.8: Rheumatoid arthritis synovial fibroblast (RASF, n=3) and osteoarthritis synovial
fibroblasts (OASF, n=3) were stimulated with the CB1 agonist ACEA (ACEA, 1× 10−6 m) or CB2
agonist GP1a (GP1a, 1× 10−7 m) for 1 to 6 h. The level of phosphorylation of extracellular-signal
regulated kinase ERK was measured with ELISA. Absorbance of the samples is given in percentage of
median of the control samples on each plate. *= p<0.05, **= p<0.01, ***= p<0.001, vs. negative
control sample (NEG).
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4.6 Conclusion: CB1 Agonism is Mainly Responsible for Ac-
tivation of MAPK and CREB in Synovial Fibroblasts
The CB1 and CB2 agonists as well as AEA phosphorylated MAPK
both in RASF and OASF. Activation levels of ERK, p38 and CREB
in RASF were significantly higher than in OASF (Figure 4.7).
Compared to the negative control samples, the CB1 agonist CP 47,497,
in particular, showed a specific activating effect on ERK and CREB
but a suppressing effect on p38. The ERK phosphorylation by AEA
was significantly lower after pretreatment with the CB2 inverse agonist
JTE than without pretreatment.
In experiments performed by Richardson et al., the CB1 and CB2 se-
lective agonist Hu210 led to a G𝛼i-protein-mediated phosphorylation
of ERK1/2 and p38, which was blocked by a CB1 antagonist but not a
CB2 antagonist (Richardson et al., 2008). Gui et al. demonstrated
that Hu-210 decreased expression of IL-6, MMP-3 and MMP-13 (Gui
et al., 2014).
The present studies were consistent with the fact, that CB1 is the main
cannabinoid receptor responsible for the phosphorylation of MAPK
and CREB. For the first time, this study also demonstrated that AEA
followed a similar pattern. However, the effects of AEA at high con-
centrations were not inhibited by CB1 but CB2 inverse agonists. This
might be because AEA at high concentration may have off-target ef-
fects that lead to the activation of TRPV1. The precise involvement
of both CB1 and CB2 receptors in anandamide activation remains to
be further studied.
4.7 Consequences on Apoptosis and Cytokine Secretion
4.7.1 CB1 Agonism Induced Apoptosis and Necrosis
In preliminary experiments, AEA and the CB1 agonist CP 47,497
induced apoptosis and necrosis by an increase of cytochrome C pro-
duction, Annexin-V and DNA presentation as well as LDH release.
When compared to untreated control samples, incubation with CB1
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agonist CP 47,497, and not the CB2 agonist GP1a, for 5 h induced an
increase of cytochrome c expression in RASF (Figure 4.9a), and after
24 h, significantly increased the number of apoptotic and necrotic cells
in OASF (Figure 4.11b). Likewise, 10µm AEA significantly fostered
necrosis in OASF after 24 h and led to a higher LDH release in both
OASF and RASF than in untreated control samples (Figures 4.9 and
4.11b.).
Anandamide induced apoptosis on a wide range of cell types. Several
mechanisms were proposed, such as MAPK p38 and JNK activation
(Sarker et al., 2003; Hsu et al., 2007; Fonseca et al., 2013), direct
involvement in the intrinsic and extrinsic apoptotic pathway (Gómez
et al., 2014), ceramide production in decidual cells (Fonseca et al.,
2013) or calcium influx through transient potential vanilloid Typ 1
receptors TRPV1 (Hu et al., 2012). Therefore, AEA might induce
apoptosis also through a CB1-mediated pathway. However, unlike the
CB1 agonist CP 47,497, AEA did not induce apoptosis but necro-
sis, probably by changing intracellular ceramids, calcium or lipid raft
structures (Grimaldi et al., 2012).
4.7.2 AEA-Attenuated Expression of Key Cytokines After
Stimulation by TNF𝛼
In comparison to unpretreated samples, pre-incubation with AEA
for 24 h tended to attenuate the increase in expression of the protein
PAI-1 and the proinflammatory cytokines IL-6, MIF, CXCL10 and C5
after stimulation with TNF𝛼 for 5min (Figure 4.12).
The plasminogen activator inhibitor-1 PAI-1 is known to be overex-
pressed in RASF and also responsible for the invasive and degradative
character of RASF (Watanabe et al., 2002; Guiducci et al., 2005).
The macrophage migration inhibitory factor (MIF-1) has a role in fi-
broblast proliferation (Lacey et al., 2003), angiogenesis (Kim et al.,
2007) and MMP production (Pakozdi et al., 2006). The C-X-C motif
chemokine 10 CXCL10 appears to have a complex role in the mor-
phogenesis of RASF in the inflammatory setting (Laragione et al.,
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Figure 4.9: Rheumatoid arthritis synovial fibroblast (RASF, n=1) were incubated with the SERCA
activator thapsigargin (THAP, 10 µm) as a positive control, the CB1 agonist CP 47,497 (CP47,
1× 10−6 m), CB2 agonist GP1a (GP1a, 1× 10−7 m) anandamide (AEA, 1× 10−7 m) or not treated
(NEG) in normoxia for 5 h. Samples are lysed and incubated on the Proteome Profiler™. Results are
given in mean pixel intensities of the respective spots of the proteins on the slides after development
of the chemiluminiscence for 5min.
Figure 4.10: Rheumatoid arthritis synovial fibroblast (RASF, n=3) and osteoarthritis synovial
fibroblasts (OASF, n=4) were incubated with anandamide (AEA) in different concentrations. After
incubation for 24 h, concentration of lactate dehydrogenase in each well was measured with the
Cytotoxicity Detection Kit. Absorbance of the samples is given in percentage of median of the control
samples on each plate. *= p<0.05, **= p<0.01, ***= p<0.001, vs. negative control sample (0).
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Figure 4.11: Rheumatoid arthritis synovial fibroblast (RASF, n=4) and osteoarthritis synovial
fibroblasts (OASF, n=5) were incubated with the CB1 agonist CP 47,497 (CB1, 1× 10−6 m), CB2
agonist GP1a (CB2, 1× 10−7 m) or anandamide (AEA, 1× 10−5 m). Using flow cytometry, Fluorescein
Isothiocyanate (FITC)-Annexin V antibody detected apoptotic cells, propidiumiodine (PI) detected
necrotic cells. *= p<0.05, **= p<0.01, vs. negative control sample (NEG). o= p<0.05, vs. CB1/CB2.
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2011). The complement factor C5 and its fragment C5a is part of
the pathogenic activation of the alternative pathway in the humoral
immune defense, which mediates local arthritis (Arend et al., 2013).
The MAPK system might be involved in the regulation of all these
proteins. Therefore, changes in the TNF𝛼-induced activation levels
of the investigated MAPK might lead to the reduced expression of
pro-inflammatory cytokines and reduced cartilage destruction.
Figure 4.12: Rheumatoid arthritis synovial fibroblast (RASF, n=1) were incubated with anandamide
AEA and TNF𝛼 for 24 h. In the supernatant, cytokines were detected using the Proteome Profiler™.
Results are given in mean pixel intensities of the respective spots of the kinases on the slides after
development of the chemiluminiscence for 5min. PAI-1 denotes plasminogen activator inhibitor-1, IL-6
interleukin 6, MCP-1 monocyte chemoattractant protein 1, MIF-1 macrophage migration inhibitory
factor 1, CXCL10 C-X-C Motif Ligand 10, s-ICAM soluble intercellular adhesion molecule and C5a
complement factor fragment 5a.
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4.8 Pathogenesis: The ECS and Immune System
The present study supports the idea of the CB2 receptor being a
counteracting component against the inflammatory process. This re-
sult might explain the increased expression of AEA in inflamed RA
tissue (Richardson et al., 2008), whose synovial concentration of
1× 10−9 m is in the range of its inhibitory effect. The actual effect,
however, has still to be determined, since AEA has been shown to sup-
press secretion of pro-inflammatory cytokines by T-cells (Cencioni et
al., 2010), but 2-arachidonylglycerol 2-AG, another endocannabinoid,
has been associated with increased inflammation of the skin (Oka et
al., 2006). In both cases, the CB2 pathway is involved. It remains
unkown whether AEA or 2-AG uses the same mechanism. Different
affinities of AEA and 2-AG might explain this fact, since AEA only
acts as a partial agonist, whereas 2-AG elicits full agonistic responses
(Gonsiorek et al., 2000).
In addition to CB1 and CB2, other receptors and non-receptor path-
ways might influence the intracellular signaling and activation, e.g.
the TRPV1 pathways (Alexander et al., 2011) or the balance of
intracellular lipids (Fonseca et al., 2013).
Regarding the systemic role of the ECS, it is known to regulate energy
homeostasis and lipid and glucose metabolism, e.g. in obesity, which
is characterised by chronic inflammation and is associated with higher
cyclooxygenase-2 and AEA levels (Hsieh et al., 2010; Silvestri et
al., 2013). So far, only local effects of cannabinoids on the arthritic
joint have been investigated. Still, its overall systemic influence and
part in RA remain to be elucidated.
4.9 Therapy: CB2 Agonism and the Anti-Inflammatory Treat-
ment
Potent, peripherally acting CB2 agonists could be appropropriate
candidates for a supportive treatment with fewer adverse effects than
traditional cannabinoids. They work in a host of cells, particularly on
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the key triumvirate of synoviocytes, leukocytes and osteoclasts. The
multicellular and pleiotropic effect of cannabinoid ligands, however,
prevents a realistic prognosis of the treatment outcome. To further
clarify local and systemic mechanisms and interactions, further stud-
ies still have to be conducted to verify the beneficial effects of cannabi-
noids.
For example, the cannabinoid Hu-308 is reported to attenuate the
IL-1𝛽 induced secretion of IL-6, MMP-3 and MMP-13 in synovial
fibroblasts (Gui et al., 2014). This suggests beneficial efficacy of
cannabinoids to stop the inflammatory vicious cycle of fibroblasts and
macrophages. In addition, secretion of degrading enzymes by fibrob-
lasts and chrondrocytes is reduced after treatment with cannabinoids
(Mbvundula et al., 2006). Also, the CB2 agonist Hu-308 inhibits
osteoclast formation (Ofek et al., 2006), suggesting that the cannabi-
noid treatment might also be beneficial for the treatment of bone loss
in RA.
Therapeutic interventions targeting the endocannabinoid system still
need to be validated for efficacy and efficiency in randomized con-
trolled trials. For the time being, it is inappropriate to exaggerate
potential advantages and underestimate the disadvantages of selective
cannabinoids, as high expectations about the anti-atheroslerotic effect
of rimonabant were disappointed in the STRADIVARIUS trial (Nis-
sen et al., 2008). While inducing more psychiatric side effects, the
CB1 antagonist rimonabant did not have a favourable influence on
the disease progression of atherosclerosis in patients with abdominal
obesity (Nissen et al., 2008).
Summary and Outlook
Fibroblast-like synoviocytes are the key aggressive players in rheuma-
toid arthritis and largely responsible for inflammation sustenance and
joint destruction. Mitigation of the aggressive behaviour and elim-
ination of the apoptotic resistance is crucial, yet still has not been
sufficiently addressed in current therapy regimes, even after the intro-
duction of biological therapies. The recent discovery of the cannabi-
noid system in the joint might address this challenge.
New innovative CB2-selective agonists with less psychoactive effects
are increasingly developed for anti-inflammatory treatment on a wide
range of cell types (Fukuda et al., 2014; Dunn et al., 2014). In
addition, regulation of the endocannabinoid levels by using FAAH in-
hibitors might also be an effective strategy. FAAH inhibitors have
shown to reduce arthritis (Kinsey et al., 2011) and to increase gluco-
corticoid effects on synovial fibroblasts (Lowin et al., 2012). Possible
treatment options might also include both strategies, since raising the
endogenous level of AEA might boost the therapeutic power of the
cannabinoid agonists.
Yet, its pleiotropic effects on various types of cells involved in RA re-
quires additional investigations in vivo to discern its usefulness in RA
therapy. The complex nature of the endocannabinoid system could be
its great strength or stumbling block.
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PTPN22 Protein Tyrosine Phosphatase, Non-
receptor type 22
RA Rheumatoid Arthritis
RASF Rheumatoid Arthritis Synovial Fibro-
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RF Rheumatoid Factor
RhoA Ras Homolog Gene Family Member A
RPMI Roswell Park Memorial Institute
RSK 90 kDa Ribosomal S6 Kinase
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